Presentations & Webinars

Safety Results with Targeted Conditioning via Iomab-B

Register for CD33 Combination Trial KOL Call

Register for Iomab-ACT Update

Mid-Point Analysis of Pivotal Phase 3 SIERRA Trial Including Material Presented at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

Dr. Sergio Giralt KOL Event – Interim Phase 3 SIERRA Results

Feasibility of Administering Iomab-B without Lead-Lined Rooms

Phase 3 SIERRA Dosimetry Data Supports Iomab-ACT Program ASH 2019

Actimab-A CLAG-M Combination Interim Results ASH 2019

Iomab-B Single Agent Activity: 2019 SOHO Annual Meeting Honorable Distinction Award Recipient

²²⁵Ac-CD38 Antibody Targeting is Effective and Well Tolerated in Experimental Models of Lymphoma and Multiple Myeloma

• « Previous
• 1
• 2
• 3
• 4
• Next »